摘要
目的探讨思密达治疗溃疡性结肠炎腹泻的机制和疗效。方法选取成年Wistar大鼠80只,用二硝基氯苯(DNCB)和乙酸(AA)复合法造模成功后1周随机分为2组,每组40只。美沙拉嗪治疗组(对照组)大鼠喂服美沙拉嗪0.2 g.kg-1.d-1,8周;思密达联合美沙拉嗪治疗组(联合治疗组)大鼠喂服美沙拉嗪0.2 g.kg-1.d-1,天然蒙脱石0.6 g.kg-1.d-1,治疗8周。分别在治疗前和治疗后记录腹泻症状变化,测定肠道黏膜通透性[以尿中乳果糖(L)/甘露醇(M)的比值表示],光镜下观察结肠组织学变化,电镜下观察肠黏膜超微结构包括微绒毛变化、组织紧密连接、上皮细胞间隙、肠基底膜细胞核分裂相和细胞凋亡情况。结果与对照组比较,联合治疗组大鼠腹泻次数恢复正常时间[(9.9±4.8)d]及黏液脓血便消失时间[(11.6±6.2)d]较对照组[(15.8±3.2)d和(16.6±3.7)d]显著缩短,差异有统计学意义(P<0.05);肠黏膜通透性[(28.6±4.2)%]较对照组[(35.6±4.7)%]显著降低(P<0.05);肠黏膜组织学缓解明显(P<0.05),超微结构恢复正常时间[(35.8±6.2)d]较对照组[(52.0±8.7)d]显著缩短(P<0.05)。结论思密达联合美沙拉嗪治疗溃疡性结肠炎,可以通过修复损伤肠黏膜屏障,降低肠黏膜通透性,从而快速缓解腹泻症状。
Objective To investigate the mechanisms and therapeutic effects of Smecta in treating diarrhea induced by Ulcerative Colitis.Methods Eighty adult Wistar rats were randomized into 2 groups（40 each） 1 week after establishment of the model using dinitrochlorobenzol（DNCB） combined with hawkinsin.Animals were administered with Mesalazine（0.2 g·kg-1·d-1） in the control group and Mesalazine（0.2 g·kg-1·d-1） combined with Smecta（0.6 g·kg-1·d-1） in the combined treatment group for 8 weeks.Diarrhoea status before and after treatment were recorded.Entero-membrane permeability（lactulose admannitol in urine） was determined.Histological changes were observed using optical microscope.Ultrastructure of the entero-mucosa,including microvillus,zonula occludens,dilated intercellular spaces,intestines basal lamina karyomitosis phasing and apoptosis status was obsreved via electron microscope.Results The combined treatment group showed significantly shorter diarrhea recovery time[（9.9±4.8）d vs（15.8±3.2）d,P0.05] and mucoid and bloody purulent stool recovery time[（11.6±6.2）d vs（16.6±3.7）d,P0.05],significantly lower entero-membrane permeability[（28.6±4.2）% vs（35.6±4.7）%,P0.05],more obvious histological improvement in the entero-mucosa（P0.05）,and shorter ultrastructure recovery time [（35.8±6.2）d vs（52.0±8.7）d,P0.05] compared with the control group.Conclusion Combination of Mesalazine and Smecta relieves diarrhea rapidly through repairment of the entero-mucosa barrier which lead to a lower level of permeability.
出处
《中国全科医学》
CAS
CSCD
北大核心
2011年第18期2031-2033,共3页
Chinese General Practice
基金
益普生腹泻基金资助项目(IDF-2010-01)
